BDBM658045 3-(5-fluoro-2-meth- yl-6-oxo-1,6- dihydropyridin-3- yl)-1-(2-methyl-4- (trifluoromethoxy)- phenyl)-6-(tri- fluoromethyl)-2,3- dihydropyrido[3,4- d]pyrimidin-4(1H)- one::US20240083896, Example 21

SMILES Cc1cc(OC(F)(F)F)ccc1N1CN(C(=O)c2cc(ncc12)C(F)(F)F)c1cc(F)c(=O)[nH]c1C

InChI Key InChIKey=BJWSTFAHQAKCBG-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 658045   

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658045(US20240083896, Example 21 | 3-(5-fluoro-2-meth- yl...)
Affinity DataIC50: 39.8nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent